Cyteir finally calls it quits after months of cost cutting

A not-so-fun year for Cyteir has reached rock bottom, with the company planning to dissolve and end all work.

Cyteir is cutting the line on CYT-0851, a phase 1 cancer med, according to a Friday announcement. The company said data from the study indicated that while “durable responses” were observed, the med was not worth advancing into further trials. It was being tested in combination with a couple of forms of chemotherapy to treat advanced ovarian cancer and other types of solid tumors.